ADSC therapy in neurodegenerative disorders
Tzu-Min Chan1, Julia Yi-Ru Chen, Li-Ing Ho
1Center for Neuropsychiatry, China Medical University Hospital, Taichung, Taiwan.
Cell Transplantation
|May 13, 2014
Summary
Adipose tissue-derived stem cells (ADSCs) show promise for treating neurodegenerative disorders like Parkinson's and Alzheimer's. Future trials may combine administration routes and cell types for enhanced therapeutic effects.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Cell Biology
Background:
- Neurodegenerative disorders are chronic, irreversible conditions with limited treatment options.
- Current therapies cannot fully mitigate symptoms of diseases like ALS, Parkinson's, Alzheimer's, and Huntington's.
- Stem cell therapy presents a promising avenue for treating these incurable neurological conditions.
Purpose of the Study:
- To review existing research on adipose tissue-derived stem cells (ADSCs) for neurodegenerative disorder treatment.
- To explore the therapeutic mechanisms of ADSCs in preclinical models.
- To propose future directions for clinical trials of ADSC-based therapies.
Main Methods:
- Review of preclinical studies utilizing ADSCs in neurodegenerative disorder models.
- Analysis of ADSC therapeutic mechanisms, including differentiation and immunomodulation.
- Synthesis of findings to inform future clinical trial design.
Main Results:
- ADSCs demonstrate potential therapeutic benefits in various neurodegenerative disorder models.
- Key mechanisms involve neuroprotection, neurogenesis, and modulation of the inflammatory environment.
- Successful preclinical outcomes support further investigation.
Conclusions:
- ADSC therapy offers a viable strategy for managing neurodegenerative diseases.
- Future clinical trials should consider combined administration routes (intracerebroventricular and intravenous) and diverse cell lineages.
- Modifying the extracellular matrix to create a homing niche may enhance therapeutic efficacy.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:22Dementia l: Introduction
33
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
33
01:23Alzheimer Disease ll: Pathophysiology
34
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
34